- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07943039
Safety and Efficacy of pALG in Conditioning Regimen for HLA-Matched Sibling HSCT in Patients With SAA or Hematological Malignancies ( pALG-MSDHSCT )
Safety and Efficacy of Anti-human T-cell Porcine Immunoglobulin in Conditioning Regimens for HLA Sibling Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Severe Aplastic Anemia (SAA)/Hematological Malignancies
This study is a single-arm clinical study designed to evaluate the safety and efficacy of p-ALG in HLA sibling identical Hematopoietic stem cell transplantation( HSCT) conditioning regimens for severe aplastic anemia (SAA)/hematologic malignancies in patients diagnosed with hematologic malignancies or sSAA requiring allogeneic HSCT from our center. Graft anti-host disease (GVHD) is the most common and severe complication of allogeneic HSCT, which significantly affects survival and quality of life. Even among recipients of HLA-identical sibling HSCT (MSD-HSCT), the incidence of acute GVHD( aGVHD) and chronic GVHD (cGVHD) reaches 40-50% and 30-70%, respectively.
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
This study was designed to explore the safety and efficacy of anti-human T cell porcine immunoglobulin p-ALG in the conditioning regimen of HLA sibling allogeneic hematopoietic stem cell transplantation for severe aplastic anemia (SAA)/hematological malignancies in 60 patients.
(1)30 patients with severe aplastic anemia type I and type II underwent MSD-HSCT, p-ALG: 20mg/kg/d for 5 days; (2)30 patients with malignant hematologic diseases, aged over 40 years, either as patients or donors, underwent sibling allogeneic transplantation, with pALG administered at 20mg/kg/d for 3 days.
The enrollment time was 24 months, and patients were followed up for 24 months to evaluate long-term efficacy.
Pharmacokinetics, inflammatory cytokines and active antibodies were measured on day 0 before pALG administration and on days 3, 5, 7, 14, 21, 28 and 60 after p-ALG administration.
Routine follow-up after transplantation was performed to assess implantation and chimerism rate, immune reconstitution, infection prevention, graft versus host disease prevention, treatment-related mortality, and overall survival.
Blood routine, urine routine, liver and kidney function, clinical manifestations and ECOG score were recorded on 28± 7,60 ± 7,90 ± 7,180 ± 7,270 ± 7,360 ± 7,450 ± 7,540 ± 7,630 ± 7,720 ±7 days after transplantation; implantation rate, OS, aGVHD, cGVHD, CMV, EB virus and other infections were recorded.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Erlie Jiang
- Número de teléfono: +86-15122538106
- Correo electrónico: jiangerlie@ihcams.ac.cn
Copia de seguridad de contactos de estudio
- Nombre: Xin Chen
- Número de teléfono: +86-13920985705
- Correo electrónico: chenxin@ihcams.ac.cn
Ubicaciones de estudio
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Porcelana, 300020
- National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Patients with severe aplastic anemia (type I/II) or hematologic malignancies undergoing HLA-matched sibling hematopoietic stem cell transplantation.
Descripción
Inclusion Criteria
- age: no age limit for severe aplastic anemia type I or II, patient or donor age>40 years for hematologic malignancies;
- gender: no gender limit;
- sibling identical hematopoietic stem cell transplantation;
- fair general status, ECOG score <2 points;
- no age limit for severe aplastic anemia, no gender limit; patient or donor age>40 years for hematologic malignancies.
Exclusion Criteria:
- uncontrolled viral, bacterial and fungal infections (disease progression during antifungal therapy);
- pregnant and lactating patients or patients unable to use appropriate contraception during treatment;
- psychiatric disorders or other medical conditions unable to comply with study treatment and monitoring requirements;
- known seropositive for HIV, active hepatitis B, active hepatitis C virus, or syphilis;
- history of tumor and treatment for any tumor within the past 3 years;
- Prior hematopoietic stem cell transplantation;
- Active heart disease, defined as one or more of the following: ① Long QTc syndrome or QTc interval>480ms;② Complete left bundle branch block, degree II or III atrioventricular block;③ History of arrhythmia requiring medication or severe clinical symptoms;④ American New York Heart Association classification ≥II; ④ Left ventricular ejection fraction less than 50%; History of myocardial infarction, unstable angina pectoris, severe unstable ventricular arrhythmia or any other arrhythmia requiring treatment, history of clinically serious pericardial disease, or ECG evidence of acute ischemic or active conduction system abnormalities within 6 months prior to enrollment.
- Subjects considered unsuitable for enrollment by the investigator.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
p-ALG cohort
(1)30 patients with severe aplastic anemia type I and type II underwent MSD-HSCT, p-ALG: 20mg/kg/d for 5 days; (2)30 patients with malignant hematologic diseases, aged over 40 years, either as patients or donors, underwent sibling allogeneic transplantation, with pALG administered at 20mg/kg/d for 3 days. |
(1)30 patients with severe aplastic anemia type I and type II underwent MSD-HSCT, p-ALG: 20mg/kg/d for 5 days; (2)30 patients with malignant hematologic diseases, aged over 40 years, either as patients or donors, underwent sibling allogeneic transplantation, with pALG administered at 20mg/kg/d for 3 days. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of acute graft-versus-host disease (aGVHD)
Periodo de tiempo: within 100 days after hematopoietic stem cell infusion
|
aGVHD was evaluated via the modified Glucksberg criteriahematopoietic stem cell transplantation, diagnosed and graded according to standard criteria. |
within 100 days after hematopoietic stem cell infusion
|
|
Incidence of chronic graft-versus-host disease (cGVHD)
Periodo de tiempo: 5 years after hematopoietic stem cell transplantation
|
cGVHD was defined in accordance with the National Institutes of Health (NIH) guidelines |
5 years after hematopoietic stem cell transplantation
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
1-year implantation rate
Periodo de tiempo: 1-year
|
The rate of primary and secondary poor engraftment of neutrophils and platelets within 1 year |
1-year
|
|
Overall survival rate
Periodo de tiempo: 5 years after hematopoietic stem cell transplantation
|
All-cause mortality from hematopoietic stem cell infusion to the last follow-up |
5 years after hematopoietic stem cell transplantation
|
|
Rejection (AA) or recurrence (malignant)
Periodo de tiempo: 5 years after hematopoietic stem cell transplantation
|
Rejection (AA) or recurrence (malignant) from hematopoietic stem cell infusion to the last follow-up |
5 years after hematopoietic stem cell transplantation
|
|
Incidence of fungal infection
Periodo de tiempo: 2 years after hematopoietic stem cell infusion
|
Incidence of fungal infection from hematopoietic stem cell infusion to the last follow-up |
2 years after hematopoietic stem cell infusion
|
|
Incidence of cytomegalovirus infection
Periodo de tiempo: 2 years after hematopoietic stem cell infusion
|
Incidence of cytomegalovirus infection from hematopoietic stem cell infusion to the last follow-up |
2 years after hematopoietic stem cell infusion
|
|
Incidence of Epstein-Barr virus infection
Periodo de tiempo: 2 years after hematopoietic stem cell infusion
|
Incidence of Epstein-Barr virus infection from hematopoietic stem cell infusion to the last follow-up |
2 years after hematopoietic stem cell infusion
|
|
Transplant-related mortality
Periodo de tiempo: 5 years after hematopoietic stem cell infusion
|
Non-relapse/progression-related death occurring within 100 days after hematopoietic stem cell infusion |
5 years after hematopoietic stem cell infusion
|
|
Drug-related toxic and side effects from hematopoietic stem cell infusion to the last
Periodo de tiempo: 2 years after hematopoietic stem cell infusion
|
Drug-related toxic and side effects from hematopoietic stem cell infusion to the last follow-up |
2 years after hematopoietic stem cell infusion
|
Colaboradores e Investigadores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- IIT2026106
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .